- Home
- VTYX vs HEQ Comparison
VTYX vs HEQ Comparison
Compare VTYX & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- HEQ
- Stock Information
- Founded
- VTYX 2018
- HEQ 2011
- Country
- VTYX United States
- HEQ United States
- Employees
- VTYX N/A
- HEQ N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- HEQ Investment Managers
- Sector
- VTYX Health Care
- HEQ Finance
- Exchange
- VTYX Nasdaq
- HEQ Nasdaq
- Market Cap
- VTYX 154.9M
- HEQ 129.0M
- IPO Year
- VTYX 2021
- HEQ N/A
- Fundamental
- Price
- VTYX $3.65
- HEQ N/A
- Analyst Decision
- VTYX Buy
- HEQ
- Analyst Count
- VTYX 3
- HEQ 0
- Target Price
- VTYX $10.00
- HEQ N/A
- AVG Volume (30 Days)
- VTYX 1.5M
- HEQ 43.1K
- Earning Date
- VTYX 11-06-2025
- HEQ 01-01-0001
- Dividend Yield
- VTYX N/A
- HEQ 9.78%
- EPS Growth
- VTYX N/A
- HEQ N/A
- EPS
- VTYX N/A
- HEQ N/A
- Revenue
- VTYX N/A
- HEQ N/A
- Revenue This Year
- VTYX N/A
- HEQ N/A
- Revenue Next Year
- VTYX N/A
- HEQ N/A
- P/E Ratio
- VTYX N/A
- HEQ N/A
- Revenue Growth
- VTYX N/A
- HEQ N/A
- 52 Week Low
- VTYX $0.78
- HEQ $9.08
- 52 Week High
- VTYX $4.05
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- VTYX 62.22
- HEQ 50.49
- Support Level
- VTYX $3.48
- HEQ $10.46
- Resistance Level
- VTYX $4.04
- HEQ $10.75
- Average True Range (ATR)
- VTYX 0.30
- HEQ 0.13
- MACD
- VTYX 0.04
- HEQ -0.00
- Stochastic Oscillator
- VTYX 72.93
- HEQ 51.69
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.